Development of a novel virus-like particle vaccine platform that mimics the immature form of alphavirus

Akane Urakami, Atsuko Sakurai, Momoko Ishikawa, Moh Lan Yap, Yevel Flores-Garcia, Yasunari Haseda, Taiki Aoshi, Fidel P Zavala, Michael G. Rossmann, Sachiko Kuno, Ryuji Ueno, Wataru Akahata

Research output: Contribution to journalArticle

Abstract

Virus-like particles (VLPs) are noninfectious multiprotein structures that are engineered to self-assemble from viral structural proteins. Here, we developed a novel VLP-based vaccine platform utilizing VLPs from the chikungunya virus. We identified two regions within the envelope protein, a structural component of chikungunya, where foreign antigens can be inserted without compromising VLP structure. Our VLP displays 480 copious copies of an inserted antigen on the VLP surface in a highly symmetric manner and is thus capable of inducing strong immune responses against any inserted antigen. Furthermore, by mimicking the structure of the immature form of the virus, we altered our VLP's in vivo dynamics and enhanced its immunogenicity. We used the circumsporozoite protein (CSP) of the Plasmodium falciparum malaria parasite as an antigen and demonstrated that our VLP-based vaccine elicits strong immune responses against CSP in animals. The sera from immunized monkeys protected mice from malaria infection. Likewise, mice vaccinated with P. yoelii CSP-containing VLPs were protected from an infectious sporozoite challenge. Hence, our uniquely engineered VLP platform can serve as a blueprint for the development of vaccines against other pathogens and diseases.

Original languageEnglish (US)
Article numbere00090-17
JournalClinical and Vaccine Immunology
Volume24
Issue number7
DOIs
StatePublished - Jul 1 2017

Fingerprint

Virus-Like Particle Vaccines
Alphavirus
Viruses
Virion
Antigens
Proteins
Vaccines
Chikungunya virus
Viral Structural Proteins
Sporozoites
Falciparum Malaria
Malaria
Haplorhini
Parasites
Blueprints
Pathogens

Keywords

  • Alphavirus
  • Chikungunya virus
  • Malaria
  • Vaccines
  • Virus-like particle

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Clinical Biochemistry
  • Microbiology (medical)

Cite this

Urakami, A., Sakurai, A., Ishikawa, M., Yap, M. L., Flores-Garcia, Y., Haseda, Y., ... Akahata, W. (2017). Development of a novel virus-like particle vaccine platform that mimics the immature form of alphavirus. Clinical and Vaccine Immunology, 24(7), [e00090-17]. https://doi.org/10.1128/CVI.00090-17

Development of a novel virus-like particle vaccine platform that mimics the immature form of alphavirus. / Urakami, Akane; Sakurai, Atsuko; Ishikawa, Momoko; Yap, Moh Lan; Flores-Garcia, Yevel; Haseda, Yasunari; Aoshi, Taiki; Zavala, Fidel P; Rossmann, Michael G.; Kuno, Sachiko; Ueno, Ryuji; Akahata, Wataru.

In: Clinical and Vaccine Immunology, Vol. 24, No. 7, e00090-17, 01.07.2017.

Research output: Contribution to journalArticle

Urakami, A, Sakurai, A, Ishikawa, M, Yap, ML, Flores-Garcia, Y, Haseda, Y, Aoshi, T, Zavala, FP, Rossmann, MG, Kuno, S, Ueno, R & Akahata, W 2017, 'Development of a novel virus-like particle vaccine platform that mimics the immature form of alphavirus', Clinical and Vaccine Immunology, vol. 24, no. 7, e00090-17. https://doi.org/10.1128/CVI.00090-17
Urakami, Akane ; Sakurai, Atsuko ; Ishikawa, Momoko ; Yap, Moh Lan ; Flores-Garcia, Yevel ; Haseda, Yasunari ; Aoshi, Taiki ; Zavala, Fidel P ; Rossmann, Michael G. ; Kuno, Sachiko ; Ueno, Ryuji ; Akahata, Wataru. / Development of a novel virus-like particle vaccine platform that mimics the immature form of alphavirus. In: Clinical and Vaccine Immunology. 2017 ; Vol. 24, No. 7.
@article{0133ab3e591842baa7d66428726eec2d,
title = "Development of a novel virus-like particle vaccine platform that mimics the immature form of alphavirus",
abstract = "Virus-like particles (VLPs) are noninfectious multiprotein structures that are engineered to self-assemble from viral structural proteins. Here, we developed a novel VLP-based vaccine platform utilizing VLPs from the chikungunya virus. We identified two regions within the envelope protein, a structural component of chikungunya, where foreign antigens can be inserted without compromising VLP structure. Our VLP displays 480 copious copies of an inserted antigen on the VLP surface in a highly symmetric manner and is thus capable of inducing strong immune responses against any inserted antigen. Furthermore, by mimicking the structure of the immature form of the virus, we altered our VLP's in vivo dynamics and enhanced its immunogenicity. We used the circumsporozoite protein (CSP) of the Plasmodium falciparum malaria parasite as an antigen and demonstrated that our VLP-based vaccine elicits strong immune responses against CSP in animals. The sera from immunized monkeys protected mice from malaria infection. Likewise, mice vaccinated with P. yoelii CSP-containing VLPs were protected from an infectious sporozoite challenge. Hence, our uniquely engineered VLP platform can serve as a blueprint for the development of vaccines against other pathogens and diseases.",
keywords = "Alphavirus, Chikungunya virus, Malaria, Vaccines, Virus-like particle",
author = "Akane Urakami and Atsuko Sakurai and Momoko Ishikawa and Yap, {Moh Lan} and Yevel Flores-Garcia and Yasunari Haseda and Taiki Aoshi and Zavala, {Fidel P} and Rossmann, {Michael G.} and Sachiko Kuno and Ryuji Ueno and Wataru Akahata",
year = "2017",
month = "7",
day = "1",
doi = "10.1128/CVI.00090-17",
language = "English (US)",
volume = "24",
journal = "Clinical and Vaccine Immunology",
issn = "1556-6811",
publisher = "American Society for Microbiology",
number = "7",

}

TY - JOUR

T1 - Development of a novel virus-like particle vaccine platform that mimics the immature form of alphavirus

AU - Urakami, Akane

AU - Sakurai, Atsuko

AU - Ishikawa, Momoko

AU - Yap, Moh Lan

AU - Flores-Garcia, Yevel

AU - Haseda, Yasunari

AU - Aoshi, Taiki

AU - Zavala, Fidel P

AU - Rossmann, Michael G.

AU - Kuno, Sachiko

AU - Ueno, Ryuji

AU - Akahata, Wataru

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Virus-like particles (VLPs) are noninfectious multiprotein structures that are engineered to self-assemble from viral structural proteins. Here, we developed a novel VLP-based vaccine platform utilizing VLPs from the chikungunya virus. We identified two regions within the envelope protein, a structural component of chikungunya, where foreign antigens can be inserted without compromising VLP structure. Our VLP displays 480 copious copies of an inserted antigen on the VLP surface in a highly symmetric manner and is thus capable of inducing strong immune responses against any inserted antigen. Furthermore, by mimicking the structure of the immature form of the virus, we altered our VLP's in vivo dynamics and enhanced its immunogenicity. We used the circumsporozoite protein (CSP) of the Plasmodium falciparum malaria parasite as an antigen and demonstrated that our VLP-based vaccine elicits strong immune responses against CSP in animals. The sera from immunized monkeys protected mice from malaria infection. Likewise, mice vaccinated with P. yoelii CSP-containing VLPs were protected from an infectious sporozoite challenge. Hence, our uniquely engineered VLP platform can serve as a blueprint for the development of vaccines against other pathogens and diseases.

AB - Virus-like particles (VLPs) are noninfectious multiprotein structures that are engineered to self-assemble from viral structural proteins. Here, we developed a novel VLP-based vaccine platform utilizing VLPs from the chikungunya virus. We identified two regions within the envelope protein, a structural component of chikungunya, where foreign antigens can be inserted without compromising VLP structure. Our VLP displays 480 copious copies of an inserted antigen on the VLP surface in a highly symmetric manner and is thus capable of inducing strong immune responses against any inserted antigen. Furthermore, by mimicking the structure of the immature form of the virus, we altered our VLP's in vivo dynamics and enhanced its immunogenicity. We used the circumsporozoite protein (CSP) of the Plasmodium falciparum malaria parasite as an antigen and demonstrated that our VLP-based vaccine elicits strong immune responses against CSP in animals. The sera from immunized monkeys protected mice from malaria infection. Likewise, mice vaccinated with P. yoelii CSP-containing VLPs were protected from an infectious sporozoite challenge. Hence, our uniquely engineered VLP platform can serve as a blueprint for the development of vaccines against other pathogens and diseases.

KW - Alphavirus

KW - Chikungunya virus

KW - Malaria

KW - Vaccines

KW - Virus-like particle

UR - http://www.scopus.com/inward/record.url?scp=85021983849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021983849&partnerID=8YFLogxK

U2 - 10.1128/CVI.00090-17

DO - 10.1128/CVI.00090-17

M3 - Article

C2 - 28515133

AN - SCOPUS:85021983849

VL - 24

JO - Clinical and Vaccine Immunology

JF - Clinical and Vaccine Immunology

SN - 1556-6811

IS - 7

M1 - e00090-17

ER -